CAP-1002 - Parent Project Muscular Dystrophy
CAP-1002, an allogeneic cell therapy from donor heart tissue, aims to reduce inflammation, muscle degeneration, and enhance muscle regeneration, potentially prolonging muscle function. A Phase 3 study, Hope-3, is recruiting, sponsored by Capricor Therapeutics.
Related Clinical Trials
Reference News
Capricor Therapeutics aligned with the FDA on the HOPE-3 trial design for CAP-1002, targeting Duchenne muscular dystrophy (DMD) treatment. The trial aims for 58 participants, with topline results expected in late 2024 and a BLA submission in 2025. Positive 24-month data from HOPE-2-OLE study showed CAP-1002's potential benefits in cardiac and skeletal function for DMD patients.
CAP-1002, an allogeneic cell therapy from donor heart tissue, aims to reduce inflammation, muscle degeneration, and enhance muscle regeneration, potentially prolonging muscle function. A Phase 3 study, Hope-3, is recruiting, sponsored by Capricor Therapeutics.